Stephen E Gitelman1, Peter A Gottlieb2, Mark R Rigby3, Eric I Felner4, Steven M Willi5, Lynda K Fisher6, Antoinette Moran7, Michael Gottschalk8, Wayne V Moore9, Ashley Pinckney10, Lynette Keyes-Elstein10, Sudeepta Aggarwal11, Deborah Phippard11, Peter H Sayre12, Linna Ding13, Jeffrey A Bluestone14, Mario R Ehlers12. 1. University of California San Francisco, San Francisco, CA, USA. Electronic address: sgitelma@peds.ucsf.edu. 2. Barbara Davis Center, University of Colorado, Aurora, CO, USA. 3. Indiana University and Riley Children's Hospital, Indianapolis, Indianapolis, IN, USA. 4. Emory University, Atlanta, GA, USA. 5. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 6. Children's Hospital of Los Angeles, Los Angeles, CA, USA. 7. University of Minnesota, Minneapolis, MN, USA. 8. University of California San Diego, San Diego, CA, USA. 9. Children's Mercy Hospital, Kansas City, MO, USA. 10. Rho Federal Systems Division, Chapel Hill, NC, USA. 11. Immune Tolerance Network, Bethesda, MD, USA. 12. Immune Tolerance Network, San Francisco, CA, USA. 13. National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. 14. University of California San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Type 1 diabetes results from T-cell-mediated destruction of β cells. Findings from preclinical studies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for reducing this autoimmune response. We assessed the safety and efficacy of rabbit ATG in preserving islet function in participants with recent-onset type 1 diabetes, and report here our 12-month results. METHODS: For this phase 2, randomised, placebo-controlled, clinical trial, we enrolled patients with recent-onset type 1 diabetes, aged 12-35 years, and with a peak C-peptide of 0.4 nM or greater on mixed meal tolerance test from 11 sites in the USA. We used a computer generated randomisation sequence to randomly assign patients (2:1, with permuted-blocks of size three or six and stratified by study site) to receive either 6.5 mg/kg ATG or placebo over a course of four days. All participants were masked and initially managed by an unmasked drug management team, which managed all aspects of the study until month 3. Thereafter, to maintain masking for diabetes management throughout the remainder of the study, participants received diabetes management from an independent, masked study physician and nurse educator. The primary endpoint was the baseline-adjusted change in 2-h area under the curve C-peptide response to mixed meal tolerance test from baseline to 12 months. Analyses were by intention to treat. This is a planned interim analysis of an on-going trial that will run for 24 months of follow-up. This study is registered with ClinicalTrials.gov, number NCT00515099. FINDINGS: Between Sept 10, 2007, and June 1, 2011, we screened 154 individuals, randomly allocating 38 to ATG and 20 toplacebo. We recorded no between-group difference in the primary endpoint: participants in the ATG group had a mean change in C-peptide area under the curve of -0.195 pmol/mL (95% CI -0.292 to -0.098) and those in the placebo group had a mean change of -0.239 pmol/mL (-0.361 to -0.118) in the placebo group (p=0.591). All except one participant in the ATG group had both cytokine release syndrome and serum sickness, which was associated with a transient rise in interleukin-6 and acute-phase proteins. Acute T cell depletion occurred in the ATG group, with slow reconstitution over 12 months. However, effector memory T cells were not depleted, and the ratio of regulatory to effector memory T cells declined in the first 6 months and stabilised thereafter. ATG-treated patients had 159 grade 3-4 adverse events, many associated with T-cell depletion, compared with 13 in the placebo group, but we detected no between-group difference in incidence of infectious diseases. INTERPRETATION: Our findings suggest that a brief course of ATG does not result in preservation of β-cell function 12 months later in patients with new-onset type 1 diabetes. Generalised T-cell depletion in the absence of specific depletion of effector memory T cells and preservation of regulatory T cells seems to be an ineffective treatment for type 1 diabetes.
RCT Entities:
BACKGROUND:Type 1 diabetes results from T-cell-mediated destruction of β cells. Findings from preclinical studies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for reducing this autoimmune response. We assessed the safety and efficacy of rabbit ATG in preserving islet function in participants with recent-onset type 1 diabetes, and report here our 12-month results. METHODS: For this phase 2, randomised, placebo-controlled, clinical trial, we enrolled patients with recent-onset type 1 diabetes, aged 12-35 years, and with a peak C-peptide of 0.4 nM or greater on mixed meal tolerance test from 11 sites in the USA. We used a computer generated randomisation sequence to randomly assign patients (2:1, with permuted-blocks of size three or six and stratified by study site) to receive either 6.5 mg/kg ATG or placebo over a course of four days. All participants were masked and initially managed by an unmasked drug management team, which managed all aspects of the study until month 3. Thereafter, to maintain masking for diabetes management throughout the remainder of the study, participants received diabetes management from an independent, masked study physician and nurse educator. The primary endpoint was the baseline-adjusted change in 2-h area under the curve C-peptide response to mixed meal tolerance test from baseline to 12 months. Analyses were by intention to treat. This is a planned interim analysis of an on-going trial that will run for 24 months of follow-up. This study is registered with ClinicalTrials.gov, number NCT00515099. FINDINGS: Between Sept 10, 2007, and June 1, 2011, we screened 154 individuals, randomly allocating 38 to ATG and 20 to placebo. We recorded no between-group difference in the primary endpoint: participants in the ATG group had a mean change in C-peptide area under the curve of -0.195 pmol/mL (95% CI -0.292 to -0.098) and those in the placebo group had a mean change of -0.239 pmol/mL (-0.361 to -0.118) in the placebo group (p=0.591). All except one participant in the ATG group had both cytokine release syndrome and serum sickness, which was associated with a transient rise in interleukin-6 and acute-phase proteins. Acute T cell depletion occurred in the ATG group, with slow reconstitution over 12 months. However, effector memory T cells were not depleted, and the ratio of regulatory to effector memory T cells declined in the first 6 months and stabilised thereafter. ATG-treated patients had 159 grade 3-4 adverse events, many associated with T-cell depletion, compared with 13 in the placebo group, but we detected no between-group difference in incidence of infectious diseases. INTERPRETATION: Our findings suggest that a brief course of ATG does not result in preservation of β-cell function 12 months later in patients with new-onset type 1 diabetes. Generalised T-cell depletion in the absence of specific depletion of effector memory T cells and preservation of regulatory T cells seems to be an ineffective treatment for type 1 diabetes.
Authors: X Préville; M Flacher; B LeMauff; S Beauchard; P Davelu; J Tiollier; J P Revillard Journal: Transplantation Date: 2001-02-15 Impact factor: 4.939
Authors: Thomas E Starzl; Noriko Murase; Kareem Abu-Elmagd; Edward A Gray; Ron Shapiro; Bijan Eghtesad; Robert J Corry; Mark L Jordan; Paulo Fontes; Tim Gayowski; Geoffrey Bond; Velma P Scantlebury; Santosh Potdar; Parmjeet Randhawa; Tong Wu; Adriana Zeevi; Michael A Nalesnik; Jennifer Woodward; Amadeo Marcos; Massimo Trucco; Anthony J Demetris; John J Fung Journal: Lancet Date: 2003-05-03 Impact factor: 79.321
Authors: Andrew L Lundquist; Ravi S Chari; James H Wood; Geraldine G Miller; Heidi M Schaefer; David S Raiford; Kelly J Wright; D Lee Gorden Journal: Liver Transpl Date: 2007-05 Impact factor: 5.799
Authors: A Bacigalupo; R Brand; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier Journal: Semin Hematol Date: 2000-01 Impact factor: 3.851
Authors: Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: Greg Simon; Matthew Parker; Vijayakumar Ramiya; Clive Wasserfall; Yanfei Huang; Damien Bresson; R Fletcher Schwartz; Martha Campbell-Thompson; Lauren Tenace; Todd Brusko; Song Xue; Abraham Scaria; Michael Lukason; Scott Eisenbeis; John Williams; Michael Clare-Salzler; Desmond Schatz; Bruce Kaplan; Matthias Von Herrath; Karl Womer; Mark A Atkinson Journal: Diabetes Date: 2007-11-26 Impact factor: 9.461
Authors: Carlos E B Couri; Maria C B Oliveira; Ana B P L Stracieri; Daniela A Moraes; Fabiano Pieroni; George M N Barros; Maria Isabel A Madeira; Kelen C R Malmegrim; Maria C Foss-Freitas; Belinda P Simões; Edson Z Martinez; Milton C Foss; Richard K Burt; Júlio C Voltarelli Journal: JAMA Date: 2009-04-15 Impact factor: 56.272
Authors: Linda A DiMeglio; Peiyao Cheng; Roy W Beck; Craig Kollman; Katrina J Ruedy; Robert Slover; Tandy Aye; Stuart A Weinzimer; Andrew A Bremer; Bruce Buckingham Journal: Pediatr Diabetes Date: 2015-02-27 Impact factor: 4.866
Authors: Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko Journal: Curr Diab Rep Date: 2018-08-30 Impact factor: 4.810
Authors: Kurt J Griffin; Paul A Thompson; Michael Gottschalk; Jennifer H Kyllo; Alex Rabinovitch Journal: Lancet Diabetes Endocrinol Date: 2014-07-02 Impact factor: 32.069